THE CLAUDIN-1 COMPANY
Treat cancer and reverse fibrosis
We are a clinical-stage biotech company with a mission to treat cancer and reverse fibrosis. To this end, we are rapidly advancing our pipeline of anti-Claudin-1 antibody-drug conjugates (ADCs) and monoclonal antibodies.
Our team is committed to unlocking the broad potential of our therapeutic target Claudin-1 and bringing new treatments to those in need.
Transformative Claudin-1 antibodies
We are the world leader in developing anti-Claudin-1 treatment. Our first-in-class antibodies specifically target exposed Claudin-1 to open the stiff extracellular matrix, block disease signaling, and in cancer, selectively kill tumor cells.
R&D pipeline
We have developed a promising pipeline of anti-Claudin-1 antibody-drug conjugates (ADCs) and antibodies. Our clinical candidates include ADC ALE.P02 for squamous cancers and monoclonal antibody lixudebart for organ fibrosis. Beyond the clinical assets, our preclinical programs feature other anti-Claudin-1 modalities including other ADCs.
Inspired leadership
Our carefully chosen team values collaboration, hard work and shares the belief that anti-Claudin-1 therapies will make a difference for patients. Our highly experienced leadership team is supported by a Board of Directors and a Scientific Advisory Board made up of industry veterans, entrepreneurs and esteemed scientists.
Alentis news
January 9, 2054
POSITIVE TOPLINE RESULTS FOR TWO FIBROSIS STUDIES OF LIXUDEBART (ALE.F02)
November 18, 2024
ALENTIS RECEIVES FDA FAST TRACK DESIGNATION FOR ALE.P02